The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated×2•Originally published 30 April 2026•Updated 30 April 2026•

1 min read

Gilead Sciences CEO Sells $1.29M in Stock Amid High Valuation Concerns

Key Facts

1Daniel Patrick O'Day, CEO of Gilead Sciences, sold 10,000 shares of company stock at a price of $129.16 per share.

2The sale took place on April 28, 2026, under a pre-arranged Rule 10b5-1 trading plan, reducing the CEO's ownership by 1.56%.

3Gilead Sciences has recorded 43 insider sells and zero insider buys over the past year.

Gilead Sciences disclosed a $1.29 million stock sale by its CEO, occurring alongside the announcement of robust fiscal 2025 performance, highlighted by $20.8 billion in HIV segment sales. Shareholders recently approved executive compensation and a new equity incentive plan, strengthening the company's governance framework. The firm demonstrated significant capital return, distributing $4 billion in dividends and repurchasing $1.9 billion of its own stock. Strategically, Gilead has expanded its clinical pipeline to 53 programs while progressing with the Arcellx acquisition to bolster its oncology portfolio. These updates shift the narrative toward operational strength and shareholder value, despite previous concerns over insider selling and a slight downward revision in 2026 EPS estimates. Investors are now weighing the aggressive R&D expansion and strong cash flows against current market valuations.

about 1 month ago

Version History

Version 2about 1 month ago

What changed: Updated the story to include strong 2025 HIV segment sales, significant dividend distributions, stock repurchases, and shareholder approval of executive incentive plans.

Version 1about 1 month ago

What changed: Updated the story to include revised FY2026 EPS estimates, the consensus price target, and details regarding the Arcellx acquisition.